Abstract:Spinocerebellar ataxia type 3/Machado–Joseph disease (SCA3/MJD) is a progressive autosomal dominant neurodegenerative disease caused by abnormal CAG repeats in the exon 10 of ATXN3. The accumulation of the mutant ataxin-3 proteins carrying expanded polyglutamine (polyQ) leads to selective degeneration of neurons. Since the pathogenesis of SCA3 has not been fully elucidated, and no effective therapies have been identified, it is crucial to investigate the pathogenesis and seek new therapeutic strategies of SCA3. Induced pluripotent stem cells (iPSCs) can be used as the ideal cell model for the molecular pathogenesis of polyQ diseases. Abnormal CAG expansions mediated by CRISPR/Cas9 genome engineering technologies have shown promising potential for the treatment of polyQ diseases, including SCA3. In this study, SCA3-iPSCs can be corrected by the replacement of the abnormal CAG expansions (74 CAG) with normal repeats (17 CAG) using CRISPR/Cas9-mediated homologous recombination (HR) strategy. Besides, corrected SCA3-iPSCs retained pluripotent and normal karyotype, which can be differentiated into a neural stem cell (NSCs) and neuronal cells, and maintained electrophysiological characteristics. The expression of differentiation markers and electrophysiological characteristics were similar among the neuronal differentiation from normal control iPSCs (Ctrl-iPSCs), SCA3-iPSCs, and isogenic control SCA3-iPSCs. Furthermore, this study proved that the phenotypic abnormalities in SCA3 neurons, including aggregated IC2-polyQ protein, decreased mitochondrial membrane potential (MMP) and glutathione expressions, increased reactive oxygen species (ROS), intracellular Ca2+ concentrations, and lipid peroxidase malondialdehyde (MDA) levels, all were rescued in the corrected SCA3-NCs. For the first time, this study demonstrated the feasibility of CRISPR/Cas9-mediated HR strategy to precisely repair SCA3-iPSCs, and reverse the corresponding abnormal disease phenotypes. In addition, the importance of genetic control using CRISPR/Cas9-mediated iPSCs for disease modeling. Our work may contribute to providing a potential ideal model for molecular mechanism research and autologous stem cell therapy of SCA3 or other polyQ diseases, and offer a good gene therapy strategy for future treatment.

Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells.

Genetic Correction of TRMU Allele Restored the Mitochondrial Dysfunction-Induced Deficiencies in Ipscs-Derived Hair Cells of Hearing-Impaired Patients.

Effects of Genetic Correction on the Differentiation of Hair Cell-Like Cells from Ipscs with MYO15A Mutation

Genetic correction of induced pluripotent stem cells from a DFNA36 patient results in morphologic and functional recovery of derived hair cell-like cells

Verification of an Ipsc Line (Lzui002-A) from a Patient with a Novel Mutation in the TBL1X Gene.

Intercellular Junctions Between Hair Cell-like Cells and Supporting Cells Derived From Human iPSCs

Generation and Genetic Correction of USH2A c.2299delG Mutation in Patient-Derived Induced Pluripotent Stem Cells

Efficient introduction of an isogenic homozygous mutation to induced pluripotent stem cells from a hereditary hearing loss family using CRISPR/Cas9 and single-stranded donor oligonucleotides

In vivo AAV9-Myo7a gene rescue restores hearing and cholinergic efferent innervation in inner hair cells

Gene therapy: an emerging therapy for hair cells regeneration in the cochlea

Treatment of autosomal recessive hearing loss via in vivo CRISPR/Cas9-mediated optimized homology-directed repair in mice

Current development of patient-specific induced pluripotent stem cells harbouring mitochondrial gene mutations and their applications in the treatment of sensorineural hearing loss

Defective mechanosensory transduction of the new inner hair cells prevents hearing recover in the damaged cochlea

Precise Detection of CRISPR-Cas9 Editing in Hair Cells in the Treatment of Autosomal Dominant Hearing Loss

Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents

Potential of Gene and Cell Therapy for Inner Ear Hair Cells

AAV-ie-K558R mediated cochlear gene therapy and hair cell regeneration

Induced Pluripotent Stem Cells: Landscape for Studying and Treating Hereditary Hearing Loss

Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor

Characterization of an induced pluripotent stem cell line (UMi040-A) bearing an auditory neuropathy spectrum disorder-associated variant in TMEM43

CRISPR/Cas9 Mediated Gene Correction Ameliorates Abnormal Phenotypes in Spinocerebellar Ataxia Type 3 Patient-Derived Induced Pluripotent Stem Cells